Viridian Therapeutics, Inc.
VRDN· Nasdaq
VRDNViridian Therapeutics, Inc.
Filed Mar 11, 2022 · 10-K · 70 days after period end · 0001590750-22-000004
derived · Computed from the longer spans the company filed.
| Metric | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019 | Q4 2018 |
|---|---|---|---|---|
| Revenue | $214.00K | $54.00K | $880.00K | $476.00K |
| Net Income | -$28.95M | -$90.74M | -$10.12M | -$10.32M |
| EPS Diluted | — | — | -$0.31 | -$0.33 |
Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2021 · filed Mar 11, 2022 · 70 d after period end
